News
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
ImmunotherapyClinical Result
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
VaccineImmunotherapyAACRClinical Result
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Clinical ResultDrug ApprovalOrphan DrugASCO
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Drug Approval
LIfT BioSciences presents preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at American Society of Gene & Cell Therapy 28th Annual Meeting, showcasing its versatility in diseases beyond oncology
ImmunotherapyAACRCell TherapyClinical Study
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
Clinical StudyFast TrackOrphan Drug
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Orphan DrugClinical StudyCell TherapyImmunotherapyASCO
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Clinical ResultImmunotherapyASCOCell Therapy
Clinical ResultOrphan DrugDrug Approval
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Clinical Study